# Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

> **NCT02522611** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 30 (estimated)

## Conditions studied

- Intractable Pain
- Palliative Care

## Interventions

- **DRUG:** Resiniferatoxin

## Key facts

- **NCT ID:** NCT02522611
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02522611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02522611, "Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02522611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*